HALO - Halozyme hits 52-week high as patent win prompts guidance raise
2024-06-06 12:51:08 ET
More on Halozyme Therapeutics
- Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript
- Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation
- Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
- Bristol-Myers says FDA has revised decision date on injected Opdivo
- Halozyme Therapeutics Non-GAAP EPS of $0.79 beats by $0.09, revenue of $195.88M misses by $3.77M